Display options
Cite
Braun DE, Karamertzanis PG, Arlin JB, et al. Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?. Cryst Growth Des. 2010;11(1):210-220doi: 10.1021/cg101162a.
Braun, D. E., Karamertzanis, P. G., Arlin, J. B., Florence, A. J., Kahlenberg, V., Tocher, D. A., Griesser, U. J., & Price, S. L. (2011). Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?. Crystal growth & design, 11(1), 210-220. https://doi.org/10.1021/cg101162a
Braun, Doris E, et al. "Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?." Crystal growth & design vol. 11,1 (2011): 210-220. doi: https://doi.org/10.1021/cg101162a
Braun DE, Karamertzanis PG, Arlin JB, Florence AJ, Kahlenberg V, Tocher DA, Griesser UJ, Price SL. Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?. Cryst Growth Des. 2011 Jan 05;11(1):210-220. doi: 10.1021/cg101162a. Epub 2010 Nov 30. PMID: 21218174; PMCID: PMC3015459.
Copy Download .nbib Format: NLM
Share it on

Cryst Growth Des. 2011 Jan 05;11(1):210-220. doi: 10.1021/cg101162a. Epub 2010 Nov 30.

Solid-State Forms of β-Resorcylic Acid: How Exhaustive Should a Polymorph Screen Be?.

Crystal growth & design

Doris E Braun, Panagiotis G Karamertzanis, Jean-Baptiste Arlin, Alastair J Florence, Volker Kahlenberg, Derek A Tocher, Ulrich J Griesser, Sarah L Price

PMID: 21218174 PMCID: PMC3015459 DOI: 10.1021/cg101162a

Abstract

An extensive experimental screen, coupled with a computational study, revealed seven new solid-state forms of β-resorcylic acid. The known, stable polymorph II° shows a reversible phase transformation to the new, kinetically stable, probably disordered high temperature form I. The study provides a consistent picture of the solid-state of β-resorcylic acid.

References

  1. Adv Drug Deliv Rev. 2001 May 16;48(1):3-26 - PubMed
  2. Acc Chem Res. 2009 Jan 20;42(1):117-26 - PubMed
  3. Acta Crystallogr B. 2002 Jun;58(Pt 3 Pt 1):380-8 - PubMed
  4. Acta Crystallogr A. 2001 Jan;57(Pt 1):47-54 - PubMed
  5. Chem Commun (Camb). 2011 Jul 7;47(25):7074-6 - PubMed
  6. Chem Commun (Camb). 2007 Oct 7;(37):3814-6 - PubMed
  7. Phys Chem Chem Phys. 2010 Aug 14;12(30):8478-90 - PubMed
  8. Adv Drug Deliv Rev. 2001 May 16;48(1):91-114 - PubMed
  9. J Comput Chem. 2005 Feb;26(3):304-24 - PubMed
  10. J Pharm Sci. 2001 Nov;90(11):1878-90 - PubMed
  11. Pharm Unserer Zeit. 1975 Sep;4(5):131-7 - PubMed
  12. J Chem Theory Comput. 2009 May 12;5(5):1432-48 - PubMed
  13. J Pharm Sci. 2006 Sep;95(9):1918-30 - PubMed
  14. Acta Crystallogr B. 2007 Apr;63(Pt 2):303-8 - PubMed
  15. J Chem Theory Comput. 2005 Nov;1(6):1128-32 - PubMed
  16. Eur J Pharm Biopharm. 2009 Jan;71(1):23-37 - PubMed
  17. Drug Discov Today. 2008 Mar;13(5-6):198-210 - PubMed
  18. Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 - PubMed

Publication Types